47 search results for: pediatric

GINA-Based Opportunities for Improved Outcomes With Effective Management of <b>Pediatric</b> Asthma in Children 6-11 Years of Age

interactivity

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

5 min

Pulmonology

Explore GINA-based recommendations for identifying risk factors, optimizing management plans, and monitoring disease progression in pediatric asthma.

expert video

Importance of Early Diagnosis of Pediatric EoE

4 min

Gastroenterology

Learn from Prof. Papadopoulou as she highlights challenges in identifying EoE in pediatric patients and the consequences of delayed diagnosis.

expert video

It Takes a Village: Patient-Centered Care in Pediatric EoE

2 min

Gastroenterology

Learn from Prof. Papadopoulou as she highlights the importance of collaboration of multiple specialties in the care of pediatric EoE.

Why Is It Important to Assess Lung Function in <b>Pediatric</b> Asthma

interactivity

Why Is It Important to Assess Lung Function in Pediatric Asthma

5 min

Pulmonology

Learn about FEV1pp and the downstream effects of lung function decline in children with severe asthma

expert video

Multifaceted Burden of Pediatric EoE

3 min

Gastroenterology

Hear from Prof. Papadopoulou as she discusses how EoE can impact different aspects of disease burden in pediatric patients and their caregivers.

expert video

Atopic Dermatitis Leads to Sleep Disruption for Children and Their Caregivers

1 min

Dermatology

Explore the impact of moderate-to-severe atopic dermatitis on sleep in pediatric patients – a short soundbite from EADV 2022.

expert video

High Burden of Atopic Dermatitis in Children

1 min

Dermatology

Explore the debilitating effects that impact day-to-day functioning in pediatric patients with atopic dermatitis – a short soundbite from EADV 2022.

videoanimation

Lung Function Assessment Is a Fundamental Component of Optimal Asthma Care

5 min

Pulmonology

Learn more about the importance of lung function assessment in optimizing care for adult and pediatric patients with asthma.

expert video

Current systemic therapies have been shown to induce remission in a subset of AD patients

5 min

Dermatology

Dr. Ramien discusses evidence suggesting early targeted inhibition in pediatric patients may prevent disease progression or lead to remission.

expert video

Most Children With Atopic Dermatitis Have Uncontrolled Disease

1 min

Dermatology

Examine evidence from PEDI-BURDEN for the risk of flares in children with moderate-to-severe atopic dermatitis – a short soundbite from EADV 2022.

expert video

Association of Younger Age of Onset With Persistence of AD

1 min

Dermatology

Dr. Paller presents the Pediatric Eczema Elective Registry (PEER) findings, which suggest early-onset of AD is associated with higher risk of persistence of disease.

expert video

Emerging Data on Advanced Systemic Treatments for Children With AD

15 min

Dermatology

This video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Eulàlia Baselga reviewing the systemic treatment landscape for children under 12 years of age with AD in the EU. Dr. Baselga also discusses the latest clinical data on the use of baricitinib in pediatric patients aged 2 to 17 years, and both clinical and real-world data on the efficacy and safety of dupilumab in pediatric patients with AD aged as young as 6 months.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AustraliaChange country/region